Tradename | Company | Number | Date | Products |
---|---|---|---|---|
AZEDRA | Progenics Pharmaceuticals | N-209607 DISCN | 2018-07-30 | 1 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
IOBENGUANE SULFATE I 131 | Sun Pharmaceutical Industries | N-020084 DISCN | 1994-03-25 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
adreview | New Drug Application | 2024-01-10 |
Expiration | Code | ||
---|---|---|---|
IOBENGUANE I-131, AZEDRA, PROGENICS PHARMS INC | |||
2025-07-30 | ODE-204 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart failure | D006333 | HP_0001635 | I50 | 1 | — | 1 | 1 | — | 3 |
Left ventricular dysfunction | D018487 | — | — | — | — | — | 1 | — | 1 |
Ventricular dysfunction | D018754 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neuroblastoma | D009447 | EFO_0000621 | — | 12 | 17 | 2 | — | 10 | 39 |
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 5 | 3 | 1 | — | 2 | 9 |
Ganglioneuroblastoma | D018305 | — | — | 1 | 1 | 1 | — | — | 3 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pheochromocytoma | D010673 | — | — | 4 | 6 | — | — | 8 | 16 |
Paraganglioma | D010235 | — | — | 4 | 4 | — | — | 4 | 10 |
Neoplasms | D009369 | — | C80 | 2 | 4 | — | — | — | 5 |
Retinoblastoma | D012175 | — | — | 1 | 1 | — | — | — | 2 |
Primitive neuroectodermal tumors | D018242 | — | — | — | 2 | — | — | — | 2 |
Neuroectodermal tumors | D017599 | — | — | — | 2 | — | — | — | 2 |
Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
Osteosarcoma | D012516 | — | — | — | 1 | — | — | — | 1 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | — | — | — | — | 1 |
Thyroid diseases | D013959 | HP_0000820 | E00-E07 | 1 | — | — | — | — | 1 |
Carcinoid tumor | D002276 | — | D3A.00 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Implantable defibrillators | D017147 | EFO_0010674 | — | — | — | — | — | 1 | 1 |
Drug common name | Iobenguane i 131 |
INN | iobenguane (131i) |
Description | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. |
Classification | Small molecule |
Drug class | iodine-containing contrast media |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | N=C(N)NCc1cccc([131I])c1 |
PDB | — |
CAS-ID | 77679-27-7 |
RxCUI | — |
ChEMBL ID | CHEMBL1615779 |
ChEBI ID | — |
PubChem CID | 60860 |
DrugBank | DB06704 |
UNII ID | Q461L7AK4R (ChemIDplus, GSRS) |